Journal article
Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.
Abstract
BACKGROUND: Single-agent taxanes are commonly used as salvage systemic therapy for patients with advanced urothelial carcinoma (UC). OBJECTIVE: To study the impact of combination chemotherapy delivering a taxane plus other chemotherapeutic agents compared with single-agent taxane as salvage therapy. DESIGN, SETTING, AND PARTICIPANTS: Individual patient-level data from phase 2 trials of salvage systemic therapy were used. INTERVENTIONS: Trials …
Authors
Sonpavde G; Pond GR; Choueiri TK; Mullane S; Niegisch G; Albers P; Necchi A; Di Lorenzo G; Buonerba C; Rozzi A
Journal
Eur Urol, Vol. 69, No. 4, pp. 634–641
Publication Date
April 2016
DOI
10.1016/j.eururo.2015.07.042
Associated Experts
Medical Subject Headings (MeSH)
Antineoplastic Combined Chemotherapy ProtocolsCarcinomaClinical Trials, Phase II as TopicDisease ProgressionDisease-Free SurvivalDocetaxelHumansKaplan-Meier EstimateMultivariate AnalysisPaclitaxelProportional Hazards ModelsRetrospective StudiesRisk FactorsSalvage TherapyTaxoidsTime FactorsTreatment OutcomeUrologic NeoplasmsUrothelium